Fig. 3.

A low frequency of CD15+ MDSCs correlates with increased overall survival. a Overall survival of cancer patients with a high (≥0.41%) or low (<0.41%) frequency of CD15+ MDSCs was plotted on a Kaplan–Meir survival curve and compared using a log-rank test. Outcomes of each group are shown in the legend (death events/total patients). b Overall survival of cancer patients diagnosed with benign cysts, pancreatic adenocarcinoma, pancreatic neuroendocrine, or other cancers (melanoma, ovarian, and colon cancer) were compared using a log-rank test. Outcomes of each group are shown in the legend (death events/total patients)